FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087482818> ?p ?o ?g. }

• W3087482818 endingPage "4489" @default.
• W3087482818 startingPage "4480" @default.
• W3087482818 abstract "This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death ligand 1 (PD-L1) tumor proportion score of 50% or higher evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). Median progression-free survival was 41.4 (95% confidence interval [CI], 4.2-42.5) months with pembrolizumab and 4.1 (95% CI, 2.8-8.3) months with chemotherapy (hazard ratio [HR], 0.27 [95% CI, 0.11-0.65]; one-sided, nominal P = .001). Median overall survival was not reached (NR) (95% CI, 22.9-NR) and 21.5 (95% CI, 5.2-35.0) months, respectively (HR, 0.39 [95% CI, 0.17-0.91]; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 pembrolizumab-treated patients (52%) and four chemotherapy-treated patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or higher. The trial is registered with Clinicaltrials.gov: NCT02142738." @default.
• W3087482818 created "2020-09-25" @default.
• W3087482818 creator A5010668788 @default.
• W3087482818 creator A5015604127 @default.
• W3087482818 creator A5021695259 @default.
• W3087482818 creator A5022022857 @default.
• W3087482818 creator A5024261346 @default.
• W3087482818 creator A5025249611 @default.
• W3087482818 creator A5032337115 @default.
• W3087482818 creator A5034276209 @default.
• W3087482818 creator A5040817459 @default.
• W3087482818 creator A5045508144 @default.
• W3087482818 creator A5045832805 @default.
• W3087482818 creator A5052246946 @default.
• W3087482818 creator A5054118501 @default.
• W3087482818 creator A5057044706 @default.
• W3087482818 creator A5062920555 @default.
• W3087482818 creator A5063817865 @default.
• W3087482818 creator A5065387771 @default.
• W3087482818 creator A5066357817 @default.
• W3087482818 creator A5068793485 @default.
• W3087482818 creator A5069589468 @default.
• W3087482818 creator A5072724155 @default.
• W3087482818 creator A5073197092 @default.
• W3087482818 creator A5077255843 @default.
• W3087482818 creator A5080846994 @default.
• W3087482818 creator A5081654329 @default.
• W3087482818 creator A5086229141 @default.
• W3087482818 date "2020-10-16" @default.
• W3087482818 modified "2023-09-27" @default.
• W3087482818 title "<i>Retracted:</i> First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset" @default.
• W3087482818 cites W1982488143 @default.
• W3087482818 cites W2026635246 @default.
• W3087482818 cites W2037418758 @default.
• W3087482818 cites W2058735415 @default.
• W3087482818 cites W2146404049 @default.
• W3087482818 cites W2198093519 @default.
• W3087482818 cites W2511043440 @default.
• W3087482818 cites W2527905628 @default.
• W3087482818 cites W2766120457 @default.
• W3087482818 cites W2796582438 @default.
• W3087482818 cites W2889646458 @default.
• W3087482818 cites W2892640821 @default.
• W3087482818 cites W2910245285 @default.
• W3087482818 cites W2913928546 @default.
• W3087482818 cites W2925446385 @default.
• W3087482818 cites W2943671268 @default.
• W3087482818 doi "https://doi.org/10.1111/cas.14647" @default.
• W3087482818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7734005" @default.
• W3087482818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34543477" @default.
• W3087482818 hasPublicationYear "2020" @default.
• W3087482818 type Work @default.
• W3087482818 sameAs 3087482818 @default.
• W3087482818 citedByCount "21" @default.
• W3087482818 countsByYear W30874828182020 @default.
• W3087482818 countsByYear W30874828182021 @default.
• W3087482818 countsByYear W30874828182022 @default.
• W3087482818 countsByYear W30874828182023 @default.
• W3087482818 crossrefType "journal-article" @default.
• W3087482818 hasAuthorship W3087482818A5010668788 @default.
• W3087482818 hasAuthorship W3087482818A5015604127 @default.
• W3087482818 hasAuthorship W3087482818A5021695259 @default.
• W3087482818 hasAuthorship W3087482818A5022022857 @default.
• W3087482818 hasAuthorship W3087482818A5024261346 @default.
• W3087482818 hasAuthorship W3087482818A5025249611 @default.
• W3087482818 hasAuthorship W3087482818A5032337115 @default.
• W3087482818 hasAuthorship W3087482818A5034276209 @default.
• W3087482818 hasAuthorship W3087482818A5040817459 @default.
• W3087482818 hasAuthorship W3087482818A5045508144 @default.
• W3087482818 hasAuthorship W3087482818A5045832805 @default.
• W3087482818 hasAuthorship W3087482818A5052246946 @default.
• W3087482818 hasAuthorship W3087482818A5054118501 @default.
• W3087482818 hasAuthorship W3087482818A5057044706 @default.
• W3087482818 hasAuthorship W3087482818A5062920555 @default.
• W3087482818 hasAuthorship W3087482818A5063817865 @default.
• W3087482818 hasAuthorship W3087482818A5065387771 @default.
• W3087482818 hasAuthorship W3087482818A5066357817 @default.
• W3087482818 hasAuthorship W3087482818A5068793485 @default.
• W3087482818 hasAuthorship W3087482818A5069589468 @default.
• W3087482818 hasAuthorship W3087482818A5072724155 @default.
• W3087482818 hasAuthorship W3087482818A5073197092 @default.
• W3087482818 hasAuthorship W3087482818A5077255843 @default.
• W3087482818 hasAuthorship W3087482818A5080846994 @default.
• W3087482818 hasAuthorship W3087482818A5081654329 @default.
• W3087482818 hasAuthorship W3087482818A5086229141 @default.
• W3087482818 hasBestOaLocation W30874828181 @default.
• W3087482818 hasConcept C121608353 @default.
• W3087482818 hasConcept C126322002 @default.
• W3087482818 hasConcept C141071460 @default.
• W3087482818 hasConcept C143998085 @default.
• W3087482818 hasConcept C168563851 @default.
• W3087482818 hasConcept C197934379 @default.
• W3087482818 hasConcept C203092338 @default.
• W3087482818 hasConcept C207103383 @default.
• W3087482818 hasConcept C2776256026 @default.
• W3087482818 hasConcept C2776694085 @default.
• W3087482818 hasConcept C2777701055 @default.
• W3087482818 hasConcept C2780057760 @default.

• next